Thomas Powell, MD
Nephrology · Columbia, SCNPI 1316968928
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations.
Across 192 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$525
- AstraZeneca$506
- Amgen$327
- Fresenius USA Marketing, Inc.$269
- Otsuka America Pharmaceutical, Inc.$203
- Calliditas Therapeutics US Inc.$162
- plus $1K from 31 others
Across 10 payments — averaging $70,073 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$701K
What the payments were for
- Food & beverage$3,35198%
- Education$672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 32 | $525 |
| AstraZeneca(2 entities) | 33 | $506 |
| Amgen(2 entities) | 20 | $327 |
| Fresenius USA Marketing, Inc. | 17 | $269 |
| Otsuka America Pharmaceutical, Inc. | 10 | $203 |
| Calliditas Therapeutics US Inc. | 8 | $162 |
| Mallinckrodt Hospital Products Inc. | 5 | $115 |
| Travere Therapeutics, Inc. | 5 | $105 |
| Bard Peripheral Vascular, Inc. | 4 | $101 |
| GSK | 5 | $89 |
| Akebia Therapeutics Inc | 6 | $85 |
| Ardelyx, Inc. | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| OPKO Pharmaceuticals, LLC | 4 | $64 |
| Vifor Pharma, Inc. | 4 | $63 |
| BD | 3 | $63 |
| Bayer | 4 | $62 |
| Sanofi | 2 | $59 |
| Aurinia Pharma U.S., Inc. | 3 | $57 |
| Inari Medical, Inc. | 1 | $44 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Exelixis Inc. | 2 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $29 |
| Cormedix Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Novo Nordisk | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Mannkind Corporation | 1 | $15 |
| Vertex | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $11 |
How this compares
$3,418 in reported general payments places this provider in the 65th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 12 | $15,983 |
| Calcitriol | 53 | $797 |
| Furosemide | 44 | $218 |
| Amlodipine Besylate | 41 | $188 |
| Lisinopril | 14 | $105 |
| Allopurinol | 13 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $506 | $15,98312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Columbia
- Renee EllisColumbia$40K
- Niall McLaughlinColumbia$15K
- Roy MathewColumbia$10K
- Thomas WheelerColumbia$9K
- Rajeev ShenoyColumbia$8K
- Nzisa MutingaColumbia$6K
- Asha BaileyColumbia$5K
- Gregory SmithColumbia$4K
- Abdul UsmaniColumbia$4K
- Carl ShealyColumbia$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.